Clinical Trial

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-04-30; most recent amendment 2026-03-05.
Status change: Not Yet Recruiting → Recruiting 2025-05-21
Trial Details
NCT Number NCT06963034
Lead Sponsor Neurocrine Biosciences
Conditions Schizophrenia
Enrollment 284 participants
Start Date 2025-05-08
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-06